The ability of IDH2 to promote resistance to cisplatin seems to provide an explanation for the poorer clinical outcome in lung cancer patients with high IDH2 expression compared to those with low IDH2 expression among the patients in the chemotherapy group. This evidence concerns the gene IDH2 and lung cancer.